Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data

Vertex Pharmaceuticals has rewarded long term shareholders, and that kind of track record naturally raises the question of whether today's valuation is still grounded in the cash the business can produce. With fresh data on its cystic fibrosis pipeline and gene therapy progress in the spotlight, investors are increasingly asking how much of that story is already priced into Vertex's cash flows. Over the past 5 years, Vertex has delivered a share price gain of 172.3%. That puts a lot of...